Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 339.

https://doi.org/10.1182/blood-2024-194832

Published: 2024

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure

Carla Minoia, Davide Bavaro, Giacomo Loseto, Crescenza Pasciolla, Lucia Diella, Carmen Pelligrino, Valentina Totaro, Vito Spada, Michele Camporeale, Immacolata Attolico, Tommasina Perrone, Felice Clemente, Francesco di Gennaro, Pellegrino Musto, Attilio Guarini, Annalisa Saracino

Blood (2022) 140 (Supplement 1): 10967–10968.

https://doi.org/10.1182/blood-2022-168809

Published: 2022

Journal Articles

Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy

Blood (2022) 140 (Supplement 1): 6504–6506.

https://doi.org/10.1182/blood-2022-166486

Published: 2022

Journal Articles

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2021) 138 (Supplement 1): 41.

https://doi.org/10.1182/blood-2021-146773

Published: 2021

Journal Articles

Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients

Blood (2021) 138 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2021-147542

Published: 2021

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Blood (2013) 122 (21): 551.

https://doi.org/10.1182/blood.V122.21.551.551

Published: 2013

Journal Articles

Impact of CD3/T Regs Ratio in Donor Graft On Survival Rates in Allogeneic Peripheral Blood Stem Cell Transplantation

Mario Delia, Domenico Pastore, Anna Mestice, Paola Carluccio, Tommasina Perrone, Francesco Gaudio, Paola Curci, Alessandra Ricco, Antonella Russo Rossi, Annamaria Giordano, Vera Carluccio, Ilaria Di Tardo, Rosa Angarano, Maria Chiara Longo, Giorgina Specchia

Blood (2012) 120 (21): 2030.

https://doi.org/10.1182/blood.V120.21.2030.2030

Published: 2012

Journal Articles

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Blood (2011) 118 (21): 777.

https://doi.org/10.1182/blood.V118.21.777.777

Published: 2011

Journal Articles

Fludarabine, Aracytine and Rituximab Based Chemotherapy In Patients with Refractory and Relapsed Mantle Cell Non-Hodgkin Lymphoma

Tommasina Perrone, Francesco Gaudio, Annamaria Giordano, Paola Curci, MD, Alessandro Spina, Clara De' Risi, Giorgina Specchia, MD

Blood (2010) 116 (21): 4892.

https://doi.org/10.1182/blood.V116.21.4892.4892

Published: 2010

Journal Articles

A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.

Blood (2009) 114 (22): 882.

https://doi.org/10.1182/blood.V114.22.882.882

Published: 2009

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm: Report of Three Cases.

Paola Carluccio, Mario Delia, Anna Mestice, Domenico Pastore, Alessandra Ricco, Annamaria Giordano, Tommasina Perrone, Francesco Gaudio, Vincenzo Liso, Giorgina Specchia

Blood (2009) 114 (22): 4703.

https://doi.org/10.1182/blood.V114.22.4703.4703

Published: 2009

Journal Articles

Activated B-Cell (ABC) Profile Does Not Have An Inferior Outcome Compared to Germinal Center B-Cell (GCB) Profile Determined by Immunohistochemistry Tissue Microarray in Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and Dose- Dense and High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT).

Blood (2008) 112 (11): 1139.

https://doi.org/10.1182/blood.V112.11.1139.1139

Published: 2008

Journal Articles

Subsets of CD34+ and Engraftment Kinetics in Allogeneic Peripheral Stem Cell Transplantation.

Domenico Pastore, Anna Mestice, Paola Carluccio, Tommasina Perrone, Manuela Leo, Silvia Sibilla, Anna M. Mazzone, Margherita Casanova, Vincenzo Liso, Giorgina Specchia

Blood (2006) 108 (11): 2954.

https://doi.org/10.1182/blood.V108.11.2954.2954

Published: 2006

NARROW

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure

Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Impact of CD3/T Regs Ratio in Donor Graft On Survival Rates in Allogeneic Peripheral Blood Stem Cell Transplantation

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Fludarabine, Aracytine and Rituximab Based Chemotherapy In Patients with Refractory and Relapsed Mantle Cell Non-Hodgkin Lymphoma

Blastic Plasmacytoid Dendritic Cell Neoplasm: Report of Three Cases.

Subsets of CD34+ and Engraftment Kinetics in Allogeneic Peripheral Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only